期刊文献+

舒尼替尼对EGFR T790M突变非小细胞肺癌H1975细胞增殖抑制作用及其机制 被引量:3

Antiproliferative effects and mechanism of sunitinib on EGFR T790M mutation in human non-small cell lung cancer cell line H1975
下载PDF
导出
摘要 目的探讨舒尼替尼(sunitinib)对EGFR T790M突变的非小细胞肺癌H1975细胞的生长抑制作用及其可能的机制。方法应用MTT法检测sunitinib作用H1975细胞的增殖抑制作用;荧光染色法观察sunitinib诱导细胞凋亡形态学的变化;流式细胞术检测细胞周期的变化,Western blot分析Bcl-2蛋白水平的变化。结果在0.75~24μmol/L浓度范围内,sunitinib明显抑制H1975细胞增殖,且具有浓度和时间依赖性,24、48、72 h的半数抑制浓度(IC50)分别为(11.70±1.49)、(6.49±0.70)、(3.54±0.28)μmol/L。荧光显微镜观察发现sunitinib能够诱导细胞出现核固缩、染色质凝集等典型的凋亡形态学改变。流式细胞仪检测细胞周期显示,sunitinib阻滞H1975细胞于G0/G1期。Western blot结果显示sunitinib能够下调Bcl-2蛋白的表达水平。结论 sunitinib对EGFR T790M突变的H1975细胞具有抑制增殖、改变细胞周期分布和诱导细胞凋亡的作用。 Objective To research the inhibitory effects and mechanism of sunitinib on acquired epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs )-resistant in human non-small cell lung cancer cell line H1975 with EGFR T790M mutation in vitro. Methods The inhibitory effects on H1975 cells exposed to sunitinib were evaluated by MTT method. The morphological changes of apoptosis induced by sunitinib were observed by fluorescence staining under the fluorescence microscope. Cell cycle was detected by flow cytometry. The Bcl-2 protein expression levels were measured by Western blot. Results The MTT assay showed sunitinib had significantly antiproliferative effects with dose-dependent and time-dependent at the concentration ranged from 0.75 to 24 μmol/L. The IC50 values of sunitinib on H1975 cells were ( 11.70 ± 1.49), (6.49 ±0. 70) and (3.54±0.28 )μmol/L at 24,48,72 h,respectively. Typical apoptotic morphologic changes were observed by fluorescence microscope, such as nuclear condensation and chromatin condensation. Flow cytometry assay showed that cell cycle was arrested at the Go/G1 phase on H1975 cells. Western blot assay indicated that sunitinib down-regulated the protein level of Bcl-2. Conclusion Sunitinib can exert inhibitory effects on acquired EGFR TKIs-resistant in human non-small cell lung cancer cell line H1975 with EGFR T790M mutation, and it also can change the distribution of cell cycle and induce apoptosis.
出处 《安徽医科大学学报》 CAS 北大核心 2011年第12期1267-1271,共5页 Acta Universitatis Medicinalis Anhui
基金 安徽省科技厅重点项目(编号:07020304102)
关键词 舒尼替尼 肺癌 非小细胞肺癌 细胞凋亡 细胞周期 BCL-2 sunitinib lung cancer non-small cell lung cancer apoptosis cell cycle Bcl-2
  • 相关文献

参考文献15

  • 1Chen H J,Mok T S,Chen Z H,et al. Clinieopathologie and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer[J]. Pathol Oncol Res,2009,15 (4) :651 -8.
  • 2Chow L Q, Eckhardt S G. Sunitinib:from rational design to clinical efficacy[J]. J Clin Oncol,2007,25(7) :884 -96.
  • 3Tassi R, Muto A, Rangan S, et al. Response and safety of sunitinib in a heavily pre-treated metastatic non-small cell lung carcinoma patient[J]. Antieancer Res,2010,30(12) :5169 -73.
  • 4Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral muhitarget tyrosine kinase inhibitor,in patients with cancer[ J ]. J Clin Oncol,2006,24 (1) :25 -35.
  • 5Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase Ⅳ tarceva lung cancer survival treatment study [ J ]. J Thorac Oncol,2010 ,5 (10) : 1616 - 22.
  • 6Sanford M, Scott L J. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer [J]. Drugs,2009,69 (16) :2303 - 28.
  • 7Pham D, Kris M G,Riely G J,et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas[ J ]. J Clin Oncol,2006,24 ( 11 ) : 1700 - 4.
  • 8Lynch T J,Adjei A A,Bunn P A Jr,et al. Summapy statement:novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents[J]. Clin Cancer Res,2006, 12(14 Pt 2) :4365s-7ls.
  • 9Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes [ J ]. Int J Cancer,2010,126(3) :651 -5.
  • 10Onitsuka T,Uramoto H, Nose N,et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status [J]. Lung Cancer, 2010,68 ( 2 ) : 198 - 203.

二级参考文献11

共引文献7

同被引文献42

  • 1王志鸿,李鲁,周乃康,邵壮,解华杰,杨帆.射频消融联合吉非替尼治疗晚期非小细胞肺癌的临床分析[J].现代生物医学进展,2011,11(S1):4672-4674. 被引量:1
  • 2Morabito A, Costanzo R, Rachiglio AM, et al. Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EG- FR mutations [ J ] J Thorac Onco1,2013 ; 8 (7) :59-60.
  • 3Lee DS, Kang JH, Lee CG, et al. Predicting survival in patients with ad- vanced non-squamous non-small cell lung cancer: validating the extent of metastasis[J]. Cancer Res Treat ,2013 ;45 (2) :95-102.
  • 4Lee E, Keam B, Kim DW, et al. Erlotinib versus gefitinib for control ofleptomeningeal carcinomatosis in non-small-cell lung cancer[ J]. J Thorac Oncol, 2013 ; 8 ( 8 ) : 1069-74.
  • 5Takaoka K, Hidaka S, Hashitani S, et al. Effect of a nitric oxide synthase inhibitor and a CXC chemokine receptor4 antagonist on tumor growth and metastasis in a xenotransplanted mouse model of adenoid cystic carcinoma of the oral floor[ J ] Int J Onco1,2013 ;43 ( 3 ) :73745.
  • 6Emam H, Zhao QL, Furusawa Y, et al. Apoptotic cell death by the novel natural compound, cinobufotalin [ J]. Chem Biol Interact,2012 ; 199 (3) : 154-60.
  • 7Jemal A,Bray F,Center M M. Global cancer statistics[J].CA Cancer J CIin,2011,(02):69-90.
  • 8Tyson L B. Non-small cell lung cancer:new hope for a chronic illness[J].Oncology Nursing Forum,2007,(05):963-970.
  • 9Ng R,Loreto M,Lee R. Brief report:Retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer(NSCLC)following failure of platinum-based chemotherapy[J].Lung Cancer,2008,(02):262-265.
  • 10McCubrey J A,Steelman L S,Chappell W H. Roles of the Raf/MEK/ERK pathway in cell growth,malignant transformation and drug resistance[J].Biochimica Et Biophysica Acta,2007,(08):1263-1284.

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部